|
1
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kerosuo L and Bronner-Fraser M: What is
bad in cancer is good in the embryo: Importance of EMT in neural
crest development. Semin Cell Dev Biol. 23:320–332. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zavadil J and Bättinger EP: TGF-beta and
epithelial-to-mesenchymal transitions. Oncogene. 24:5764–5774.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kang Y and Massague J:
Epithelial-mesenchymal transitions: Twist in development and
metastasis. Cell. 118:277–279. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hugo H, Ackland ML, Blick T, Lawrence MG,
Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal
and mesenchymal-epithelial transitions in carcinoma progression. J
Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lipschutz JH: Molecular development of the
kidney: A review of the results of gene disruption studies. Am J
Kidney Dis. 31:383–397. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sullivan JP, Minna JD and Shay JW:
Evidence for self-renewing lung cancer stem cells and their
implications in tumor initiation, progression, and targeted
therapy. Cancer Metastasis Rev. 29:61–72. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiang W, Peng J, Zhang Y, Cho WC and Jin
K: The implications of cancer stem cells for cancer therapy. Int J
Mol Sci. 13:16636–16657. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lam WK and Watkins DN: Lung cancer: Future
directions. Respirology. 12:471–477. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II,
Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition
derived from repeated exposure to gefitinib determines the
sensitivity to EGFR inhibitors in A549, a non-small cell lung
cancer cell line. Lung Cancer. 63:219–226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seo DC, Sung JM, Cho HJ, Yi H, Seo KH,
Choi IS, Kim DK, Kim JS, Abd El-Aty AM and Shin HC: Gene expression
profiling of cancer stem cell in human lung adenocarcinoma A549
cells. Mol Cancer. 6:752007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Borthwick LA, Gardner A, De Soyza A, Mann
DA and Fisher AJ: Transforming growth factor-β1 (TGF-β1) driven
epithelial to mesenchymal transition (EMT) is accentuated by tumour
necrosis factor α (TNFα) via crosstalk between the SMAD and NF-κB
pathways. Cancer Microenviron. 5:45–57. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim NH, Kim SK, Kim DS, Zhang D, Park JA,
Yi H, Kim JS and Shin HC: Anti-proliferative action of
IL-6R-targeted antibody tocilizumab for non-small cell lung cancer
cells. Oncol Lett. 9:2283–2288. 2015.PubMed/NCBI
|
|
20
|
Chen L, Zhang JJ and Huang XY: cAMP
inhibits cell migration by interfering with Rac-induced
lamellipodium formation. J Biol Chem. 283:13799–13805. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pore MM, Buikema L, Hiltermann T and Kruyt
F: TGF beta-mediated epithelial to mesenchymal transition in non
small cell lung cancer: Effects on stemness, invasiveness and
chemotherapy sensitivity. Cancer Res. 72:24022012. View Article : Google Scholar
|
|
22
|
Zheng Y, de la Cruz CC, Sayles LC,
Alleyne-Chin C, Vaka D, Knaak TD, Bigos M, Xu Y, Hoang CD, Shrager
JB, et al: A rare population of CD24(+)ITGB4(+)Notch(hi) cells
drives tumor propagation in NSCLC and requires Notch3 for
self-renewal. Cancer Cell. 24:59–74. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roudi R, Madjd Z, Ebrahimi M, Samani FS
and Samadikuchaksaraei A: CD44 and CD24 cannot act as cancer stem
cell markers in human lung adenocarcinoma cell line A549. Cell Mol
Biol Lett. 19:23–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Scheel C and Weinberg RA: Cancer stem
cells and epithelial-mesenchymal transition: Concepts and molecular
links. Semin Cancer Biol. 22:396–403. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiao D and He J: Epithelial mesenchymal
transition and lung cancer. J Thorac Dis. 2:154–159.
2010.PubMed/NCBI
|
|
26
|
Shi Y and Massagué J: Mechanisms of
TGF-beta signaling from cell membrane to the nucleus. Cell.
113:685–700. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fuxe J, Vincent T and de Herreros A
Garcia: Transcriptional crosstalk between TGF-β and stem cell
pathways in tumor cell invasion: Role of EMT promoting Smad
complexes. Cell Cycle. 9:2363–2374. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu RY, Zeng Y, Lei Z, Wang L, Yang H, Liu
Z, Zhao J and Zhang HT: JAK/STAT3 signaling is required for
TGF-β-induced epithelial-mesenchymal transition in lung cancer
cells. Int J Oncol. 44:1643–1651. 2014.PubMed/NCBI
|
|
29
|
Xie L, Law BK, Chytil AM, Brown KA, Aakre
ME and Moses HL: Activation of the Erk pathway is required for
TGF-beta1-induced EMT in vitro. Neoplasia. 6:603–610. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lan Y, Zhou Q and Wu ZL: NF-kappa B
involved in transcription enhancement of TGF-beta 1 induced by
Ox-LDL in rat mesangial cells. Chin Med J (Engl). 117:225–230.
2004.PubMed/NCBI
|
|
31
|
Lee J, Choi JH and Joo CK: TGF-β1
regulates cell fate during epithelial-mesenchymal transition by
upregulating survivin. Cell Death Dis. 4:e7142013. View Article : Google Scholar : PubMed/NCBI
|
